

Patent

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

.....

Applicants : Mark E. Duggan, et al

Int'l Appln.  
No. : PCT/US2004/008627

Int'l Date  
Filed : 22 March 2004 (22/03/2004)

Serial No. : (To be assigned) Case No.: 21298P

Filed : September 26, 2005

For : BENZAMIDE MODULATORS OF METABOTROPIC  
GLUTAMATE RECEPTORS

.....

Commissioner for Patents  
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE  
DATE OF DEPOSIT 9-26-2005  
EXPRESS MAIL NO. E2989587624 US  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"  
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VIRGINIA 22313-1450.  
MAILED BY Christine Cuffe  
DATE 9-26-05

JC09 Rec'd PCT/PTO 26 SEP 2005

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 

J. Eric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: September 26, 2005

## INFORMATION DISCLOSURE

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

10/550968

**Application Number:**

en JC09 Rec'd PCT/PTO 26 SEP 2005

**Filing Date**

September 26, 2005

**First Named Inventor**

Mark E. Duggan, et al.

## Group Art Unit

**Examiner Name**

Sheet

1

of

**1**

Attorney Docket Number

21298P

Examiner  
Initials\*Cite  
No.

**Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.**

MANO, P. De, et al, The constitution of isamic acid, Canadian Journal of Chemistry, 1967, Vol 45, pages 2177-2190.

ROSEVEAR, J. et al, A comparison of the reactions of some Ethyl N-Arylcarbamates with Those of the Corresponding Acetanilides. II\* Amidomethylation with N-Hydroxymethylphthalimide, Australian Journal of Chemistry, 1990, Vol 43, No. 2, pages 339-53.

BEDDOES, R. L., et al, Synthesis of 2,3,5,6-Tetrahydro-1H, 4H, 11CH-3a,6a, 11b-TRIAZBENZ(de) ANTHRACENE (5) AND X-RAY CRYSTAL STRUCTURE DETERMINATION OF (5), HEXAHYDRO-1H,4H,7H,9bH-3a,6a,9a-TRIAZAPHENALENE (1), BENZO(B)-1,5,9-TRIAZADODECANE, N,N',N"-TRITOSYLAMIDE, AND OF 1,5,9, TRIAZADOODECANE N,N',N"-TRITOSYLAMIDE., Tetrahedron, 1987, Vol 43, No. 8, pages 1903-1920.

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO:** Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005